CoChat

Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases

Open access
Tsuchiya, Atsunori, Takeuchi, Suguru, Iwasawa, Takahiro, Kumagai, Masaru, Sato, Takeki, Motegi, Satoko, Ishii, Yui, Koseki, Youhei, Tomiyoshi, Kei, Natsui, Kazuki, Takeda, Nobutaka, Yoshida, Yuki, Yamazaki, Fusako, Kojima, Yuichi, Watanabe, Yusuke, Kimura, Naruhiro, Tominaga, Kentaro, Kamimura, Hiroteru, Takamura, Masaaki, Terai, Shuji · 2020 · Inflammation and Regeneration
Cited by 79

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions and must be mitigated or resolved as soon as possible. Mesenchymal stem cells (MSCs) and their exosomes can affect immune cells by inducing anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells, and can inactivate T cells. Hence, they are potential candidate agents for treatment of severe cases of COVID-19. In this review, we report the background of severe cases of COVID-19, basic aspects and mechanisms of action of MSCs and their exosomes, and discuss basic and clinical studies based on MSCs and exosomes for influenza-induced ARDS. Finally, we report the potential of MSC and exosome therapy in severe cases of COVID-19 in recently initiated or planned clinical trials of MSCs (33 trials) and exosomes (1 trial) registered in 13 countries on ClinicalTrials.gov.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s41232-020-00121-y

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 79

Metadata

Authors
Tsuchiya, A., Takeuchi, S., Iwasawa, T., Kumagai, M., Sato, T., Motegi, S., Ishii, Y., Koseki, Y., Tomiyoshi, K., Natsui, K., Takeda, N., Yoshida, Y., Yamazaki, F., Kojima, Y., Watanabe, Y., Kimura, N., Tominaga, K., Kamimura, H., Takamura, M., & Terai, S.
Venue
Inflammation and Regeneration
Published
2020-06-22
Volume
40
Issue
1
Pages
14-14
ISSN
  • 1346-8022 (ISSN-L)
  • 1880-8190
OpenAlex
W3036334165
Cited by
79
References
8
FWCI
7.32
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. https://app.cochat.ai/papers/10.1186/s41232-020-00121-y
The paper
Tsuchiya, A., Takeuchi, S., Iwasawa, T., Kumagai, M., Sato, T., Motegi, S., Ishii, Y., Koseki, Y., Tomiyoshi, K., Natsui, K., Takeda, N., Yoshida, Y., Yamazaki, F., Kojima, Y., Watanabe, Y., Kimura, N., Tominaga, K., Kamimura, H., Takamura, M., & Terai, S. (2020). Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflammation and Regeneration. https://doi.org/10.1186/s41232-020-00121-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.